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Background: Wilson’s disease (WD) is an autosomal recessive defect of cellular 
copper export. Early diagnosis in children is difficult due to its obscure clinical pres-
entations. The efficacy of zinc salts is well documented, although there are limited 
data concerning zinc use in pediatric patients with WD.
Methods: We performed a retrospective analysis of clinical features, laboratory results 
and treatment responses in children with WD diagnosed at Taichung Veterans General 
Hospital between 1996 and 2008. Diagnosis was established by low serum ceruloplas-
min, high 24-hour urinary copper excretion, presence of Kayser-Fleischer rings, and 
mutation analysis.
Results: Eleven children were included in this study. The main initial presentations 
were impaired liver function tests (6/11) and hemolytic anemia (2/11). Gene studies 
in seven children showed six different mutations (G934D, R778Q, C490X, 304insC, 
IVS4-1 G > C, P992I) and one possible novel mutation (L1181P). All patients had im-
proved liver function tests and hemoglobin levels after treatment with D-penicillamine, 
trientine and zinc supplement therapy. During a mean period of 3.4 ± 2.1 years with 
zinc therapy, six patients had serum zinc levels above the normal limit, and seven 
patients had serum copper levels below the normal range.
Conclusion: Serum ceruloplasmin and 24-hour urinary copper examinations could 
be used to rule out WD in children with chronic hepatitis and hemolytic anemia. 
Gene analysis is helpful for prompt diagnosis of asymptomatic siblings and patients 
with atypical features. Zinc treatment is generally safe in pediatric patients with 
WD. However, its adverse effects should be monitored.
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1.  Introduction
Wilson’s disease (WD) is an autosomal recessive 
defect of cellular copper export related to the loss 
of functional ATP7B protein.1,2 The worldwide 
prevalence is 1 in 35,000−100,000 live births.3 The 
two most fundamental disturbances of copper me-
tabolism in patients with this disorder are reduc-
tions in the rate of incorporation into ceruloplasmin 
and in biliary excretion of copper, leading to copper 
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accumulation.4 The clinical manifestations result 
from copper accumulation in various organs, with the 
most common presentations being hepatic or neuro-
psychiatric.5,6 The signs and symptoms caused by 
copper deposition develop over a period of time, and 
WD is therefore difficult to diagnose in pediatric pa-
tients because of its obscure clinical presentations 
during the early stage of this disorder.7 In children, it 
usually presents after 3 years of age with either 
incidental findings of abnormal liver function or as 
chronic disease, and rarely as hemolytic anemia 
and acute hepatic failure.6 According to the guide-
lines of the American Association for the Study of 
Liver Disease (AASLD), genetic analysis is valuable for 
the diagnosis of asymptomatic siblings and patients 
presenting with atypical features of WD.8 Although 
there have been several reports on children with WD 
in Asia,9,10 studies of genetic diagnosis of WD are rare. 
Early diagnosis of WD is crucial because the disease 
may be fatal if left untreated.1,11 Although zinc ther-
apy is effective for children with WD, it may cause 
copper deficiency and excess of serum zinc.12 In this 
study, we investigated the clinical features, diag-
nosis, genetic analysis and therapeutic outcome in 
children with WD.
2. Materials and Methods
2.1. Study population and diagnosis
We performed a retrospective analysis of the clinical 
presentations, laboratory findings, diagnosis, and 
therapeutic outcomes of pediatric patients with WD 
diagnosed at Taichung Veterans General Hospital 
between 1996 and 2008. The diagnosis was based on 
a combination of clinical, biochemical and genetic 
evaluations. These included low serum ceruloplas-
min, high 24-hour urinary copper excretion, presence 
of Kayser-Fleischer rings (K-F rings), histologic signs 
of chronic hepatitis, and detection of gene muta-
tions. With regard to genetic analysis for confirma-
tion of diagnosis, the most common Taiwanese 
mut ation positions for WD, including exons 2, 3, 5, 8, 
12, 13, 16 and 18 of ATP7B, were screened by direct 
DNA sequencing.4,13 The new Wilson index scoring 
system was used to evaluate the severity of the dis-
ease in our patients. Patients with a new Wilson index 
score of 11 or above were recommended to receive 
a liver transplant.6
2.2. Treatment and follow-up
All patients in this study initially received D-
penicillamine (D-PCN) or trientine therapy, with or 
without zinc. Maintenance therapy with zinc ace-
tate alone began if there were no signs of hepatic 
decompensation, and was administered at a dosage 
of elemental zinc acetate of 25 mg twice a day, until 
the age of 6 years, 25 mg three times a day between 
the ages of 7 and 16 years or until the child attained 
a body weight of 56.7 kg (125 pounds), and 50 mg 
three times a day thereafter.12,14 We analyzed serum 
levels of copper and zinc, blood cell counts, and 
liver function tests during therapy.
3. Results
3.1.  Clinical presentations and 
laboratory data
Eleven children, including nine boys and two girls, 
with a mean age of 10.0 ± 5.3 years (range, 2.5−17.7 
years) were included in this study. Three of them 
were under 5 years old at diagnosis. The interval from 
symptom onset to diagnosis was 8.8 ± 1.3 months. 
The initial presentations were: impaired liver func-
tion tests (6/11), hemolytic anemia (2/11), fulminant 
hepatic failure (1/11) and liver cirrhosis (1/11). Case 
3 was diagnosed because his brother had WD. None 
of them had neurologic symptoms or signs at pres-
entation. Low serum ceruloplasmin and high 24-hour 
urinary copper excretion were noted in all patients 
except one, whose ceruloplasmin was not checked. 
Levels of urinary copper exceeded 100 μg/24 hours in 
all patients. Nine patients underwent liver biopsies, 
and the most common pathologic findings were 
chronic hepatitis (7/9) and steatosis (5/9; Table 1).
3.2. Diagnosis
Genotyping was performed in seven patients (cases 2, 
3, 5, 6, 7, 8 and 9), and all patients showed mutations 
in both alleles. Of the seven different mutations iden-
tified, six known mutations were detected: G934D, 
R778Q, C490X, 304insC, IVS4-1 G > C, P992I, as well as 
one possible novel mutation L1181P (Table 2). Cases 
4 and 11 were diagnosed on the basis of the combi-
nation of low serum ceruloplasmin, high 24-hour uri-
nary copper, and the presence of K-F rings, meeting 
the criteria of the AASLD’s guidelines. Although case 
1 only had data for low serum ceruloplasmin and high 
24-hour urinary copper, his liver function parameters 
improved to a stable condition after D-PCN and zinc 
therapy during an 11-year follow-up period. The clini-
cal course was thus compatible with a diagnosis of 
WD. Case 10 had 24-hour urinary copper levels well in 
excess of 1600 μg/24 hours. This finding excluded the 
possibility of autoimmune hepatitis, primary scle-
rosing cholangitis, and other causes of acute liver 
failure,8 which are associated with 24-hour urinary 
copper levels below 1600 μg/24 hours. An alkaline 
phosphatase/total bilirubin ratio of less than 2.0 also 
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provided 100% sensitivity and specificity for differ-
entiating fulminant hepatic failure caused by WD 
from other disorders.15 The ratio in this case was 
1.02, which was consistent with a diagnosis of WD.
3.3. Treatment and outcome of follow-up
Only Case 10 had a new Wilson index score of more 
than 11, and died of fulminant hepatic failure before 
diagnosis of WD. Case 11 had received a liver trans-
plantation 1 month after diagnosis. All patients ini-
tially received D-PCN or trientine therapy with (1/9) 
or without zinc (8/9). Maintenance therapy with 
zinc alone began if there were no signs of hepatic 
decompensation. The total therapeutic duration 
ranged from 0.2−11.3 years (mean duration, 5.1 ± 4.1 
years). All patients showed improved liver function 
tests, but the asparate aminotransferase/alanine 
aminotransferase ratio remained elevated in three 
patients (Table 3).
Zinc therapy was given for 0.1−5.3 years (mean 
period, 3.4 ± 2.1 years). Seven of the nine patients 
had serum copper levels below the normal range, 
and six of the eight had serum zinc levels above the 
upper limit. However, none had symptoms of zinc 
toxicity such as abdominal pain, diarrhea, nausea or 
vomiting, or symptoms of copper deficiency such as 
anemia, leukopenia or neurologic manifestations 
(including ataxia, neuropathy or cognitive deficits; 
Table 4).
4. Discussion
Although there have been several reports on chil-
dren with WD in Asia,9,10 studies that include the 
Table 1  Clinical features and laboratory examinations in the 11 patients with Wilson’s disease*
No.
 
Sex
 
Initial
 Time from Serum 
Urine copper
 
Pathology
 
Gene
  
presentation
 S/S to Dx ceruloplasmin 
(μg/24 h)  mutation
   (mo) (g/L)
1 M Impaired LFT 4 Undetectable 775.0 CH,S ND
2 M Hemolytic anemia 53 Undetectable 462.0 CH,S G934D/R778Q
3 M Family history: +  1 Undetectable 294.0 CH,S G934D/R778Q
4 F Hemolytic anemia 1 Undetectable 3075.0 CH,LC ND
5 M Impaired LFT 5 Undetectable 112.0 CH 304insC/IVS4-1 G C
6 F Impaired LFT 8 0.11 568.0 CH,S IVS4-1 G C/P992I
7 M Impaired LFT 3 Undetectable 223.2 CH,S G943D/C490X
8 M Impaired LFT 4 Undetectable 350.8 ND IVS4-1G C/P992I
9 M Impaired LFT 8 Undetectable 358.8 ND P992L/L1181P
10 M FH 1 ND 8274.0 FH ND
11 M LC 1 Undetectable 629.9 LC ND
*Diagnostic criteria of Wilson's disease: serum ceruloplasmin < 0.2 g/L, urine copper > 100 μg/24 hr. LFT = liver function tests; CH = chronic 
hepatitis; S = steatosis; LC = liver cirrhosis; FH = fulminant hepatitis; ND = not done; S/S = symptoms/signs; Dx = diagnosis.
Table 2  Mutations identified in Wilson’s disease (WD) chromosomes
Mutation Sequence Exon Predicted effect
 Frequency of associated 
    WD chromosomes
Missense    
 G943D GGT GAT 12 Disrupts Tm5 3/14
 R778Q CGG CAG 8 Disrupts Tm4 2/14
 P992L CCC CTC 13 Disrupts cation channel and Tm6 3/14
Nonsense    
 C490X TGC TGA 3 Truncates protein 1/14
Insertion    
 2304insC ACGCCCCCCCATG 8 Frameshift 1/14
Splicing    
 IVS4 -1 G > C gttgcagATCACA 5 Skips exon 5 3/14
Novel    
 L1181P CTG CCG 16 Disrupts ATP binding 1/14
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genetic diagnosis of WD are rare. Based on the di-
agnostic criteria of AASLD (2008),8 WD can be diag-
nosed by the combination of K-F rings, low serum 
ceruloplasmin and high 24-hour urinary copper. If 
these three criteria are not fully met, molecular test-
ing and analysis of copper levels in dry liver should be 
performed to confirm the diagnosis. The dry liver 
copper exam is invasive and not always available, 
and K-F rings are rare in childhood.16 Thus, geno-
typing studies play an important role in the diag-
nosis of children with atypical features. Moreover, WD 
could be diagnosed solely by genetic analysis, even 
if the other criteria are not fulfilled.8,17
Early diagnosis is critically important for the 
treatment of WD, in order to avoid severe compli-
cations.16 Because the symptoms caused by copper 
deposition develop over time, K-F rings and neuro-
logic symptoms often do not appear until adoles-
cence, and thus WD is difficult to diagnose in children 
due to its obscure clinical manifestations.7 The most 
common initial presentation in children with WD is 
impaired liver function tests,16 and WD presenting 
with hemolytic anemia is often overlooked.18 The 
AASLD guidelines suggest that the first lines of 
screening for WD should be serum ceruloplasmin, 
24-hour urinary copper, and slit-lamp examination.8 
In this study, case 1 was diagnosed as idiopathic 
hemolytic anemia rather than WD until 4.4 years 
after the onset of symptoms. However, the last pa-
tient (case 4) presenting as hemolytic anemia was 
diagnosed within weeks. Thus, serum ceruloplasmin 
and 24-hour urinary copper examinations should be 
Table 3  Liver function tests upon admission and after therapy
 Upon admission After therapy
 
GOT/GPT
 γ-GT Total WBC  Albumin New GOT/GPT γ-GT Total Duration of
 
(U/L)
 
(U/L)
 bilirubin 
(˜109/L) INR (g/L) Wilson (U/L) (U/L) bilirubin therapy
No.
   (μmol/L)    index   (μmol/L) (yr)
1 95/306 44 8.6 6.900 0.84 42 2 24/32 19 15.4 11.3
2 11/17 13 47.9 27.770 1.72 18 10 21/31 44 6.8 9.7
3 34/39 12 6.8 7.300 1.22 47 1 15/16 18 6.8 8.5
4 35/19 10 58.2 8.200 1.60 24 5 22/22 24 10.3 10.0
5 102/319 114 6.8 11.430 1.02 45 4 39/63 26 5.1 3.6
6 117/260 51 5.1 7.500 0.88 46 2 29/25 15 10.3 2.4
7 783/816 34 5.1 7.800 1.05 42 6 38/30 8 1.7 1.7
8 95/194 99 25.7 4.550 − 49 0 60/105 61 12.0 1.5
9 160/212 27 10.3 10.200 − 49 4 63/89 27 13.7 0.2
10 6736/6352 216 466.9 2.000 2.16 42 12 − − − −
11 50/55 108 10.3/3.4 4.500 1.31 26 3 − − − −
GOT/GPT = glutamic-oxalocetic transaminase/glutamic-pyruvic transaminase; γ-GT = γ-glutamyl transpeptidase; WBC = white blood 
cell; INR = international normalized ratio.
Table 4  Blood cell counts before and after therapy
Case 1 2* 3 4* 5† 6 7 8 9
Pre-therapeutic  138 52 136 77 124 137 126 162 143
 Hb (mg/L)
Post-therapeutic  154 136 142 134 116 132 124 162 129
 Hb (mg/L)
Post-therapeutic 7.000 7.900 7.300 5.000 5.700 7.700 7.900 4.100 11.000
 WBC (˜109/L)
Post-therapeutic 273 339 267 200 424 293 408 193 434
 platelet (˜109/L)
Serum copper‡ 1.6 6.0 3.8 10.2 9.7 13.0 4.6 11.0 5.5
 (μmol/L)
Serum zinc§ 24.0 17.0 29.5 13.6 29.8 25.7 25.2 31.2 −
 (μmol/L)
Duration of zinc 5.0 5.0 5.3 6.0 3.5 2.2 1.6 1.5 0.1
 therapy (yr)
*Cases 2 and 4 were patients with hemolytic anemia; †case 5 was a patient with thalassemia; ‡normal range of serum copper: 
11.0−23.6 μmol/L; §normal range of serum zinc: 10.7−18.5 μmol/L. Hb = hemoglobin.
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considered in patients with chronic hepatitis of un-
known etiology, or hemolytic anemia. In addition, 
diagnosis should include early genetic screening if 
the clinical criteria are not fulfilled.
DNA sequencing for disease diagnosis is currently 
convenient and available; genetic diagnosis of WD 
can therefore be applied widely in asymptomatic 
siblings and patients with atypical features. Previous 
studies have shown that genes mutated in Taiwanese 
patients with WD were located in specific exons.4,13 
The observed mutations differed from those detected 
in either European or North American patients.19,20 
This finding suggests that the mutation spectrum of 
WD may follow a population-dependent pattern. 
These exons should therefore be screened initially 
in children in Taiwan with suspected WD, in order to 
shorten the detection time and decrease the cost. 
Early intervention could reduce the damage caused 
by copper deposition, as well as the incidence of 
end-stage liver disease. The discovery of the WD gene 
is thus important for opening up a new molecular 
diagnostic approach, which may be invaluable in the 
early diagnosis of WD in children with obscure clinical 
manifestations, and could also form the basis of 
future gene therapies.21
The currently approved treatments for WD in-
clude D-PCN, zinc acetate and trientine.22−24 How-
ever, chelating therapy with D-PCN or trientine 
may be associated with a risk of central nervous 
system deterioration.25 Zinc is currently the rec-
ommended therapy for long-term management of 
WD and presymptomatic Wilsonian patients.26 In 
our experience, all patients showed improved liver 
function tests after therapy. Furthermore, the he-
moglobin level in two patients with hemolytic ane-
mia was restored without the need for blood 
transfusions. The most common reported adverse 
effect of zinc therapy is mild and transient gastric 
disturbance, and the first signs of clinical copper 
deficiency are anemia and leucopenia.12 All the 
children in the current study tolerated zinc therapy 
well, even though their serum zinc levels were 
above the normal limit. Although all patients had 
low levels of serum copper, the hemoglobin levels 
during the follow-up period were within the normal 
limits, except in one patient with thalassemia. In 
addition, white cell and platelet counts did not show 
significant abnormalities. However, several reports 
of morbidity and mortality after zinc therapy have 
been noted.27−29 Since zinc therapy is lifelong,8 zinc 
excess and copper deficiency may become a prob-
lem. A previous study30 showed that low-dose zinc 
administration could also be effective for the treat-
ment of WD, and could reduce the effects due to 
zinc excess and copper deficiency. Further studies 
are required to determine the exact recommended 
zinc dosage for Taiwanese children with WD.
In conclusion, children with chronic hepatitis and 
hemolytic anemia should receive serum ceruloplas-
min and 24-hour urinary copper examinations to rule 
out a diagnosis of WD. Prompt diagnosis can help to 
prevent fatal complications of WD, and genetic 
screening may thus be helpful in asymptomatic sib-
lings and patients with atypical features. Long-term 
follow-up is required to monitor the adverse effects 
of zinc excess and copper deficiency. Further stud-
ies are required to establish a suitable zinc dosage 
for long-term treatment of pediatric WD patients.
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